BioSkryb Completes Move into New Global Headquarters in Durham, N.C.
Move supports company’s multi-year strategic growth initiative; advances retention, attraction, and expansion of the team; enhances the ability to serve customers; and demonstrates Company's commitment to the region
DURHAM, N.C., October 12, 2021 – BioSkryb Genomics, Inc., today announced the relocation and expansion of its corporate headquarters and research center in Durham, N.C. to advance the growth and operations of the company. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level.
“This move into a larger, modern space represents the recent growth of the company and our plans to continue expansion of our team of dedicated researchers, engineers, and highly-skilled personnel to support product development, sales, and service,” said Rob Kaizerman, Chief Operating Officer of BioSkryb Genomics. “By bringing the BioSkryb team together under one roof, we can better deliver on our commitment to developing and delivering high resolution research tools and clinical diagnostics for cancer genomics, preimplantation genetic testing, and other applications.”
The 19,500-square-foot headquarters and innovation space, located in Durham, provides a modern workspace designed for collaboration and company growth. The innovation space includes all new equipment and facilities to support BioSkryb’s new product R&D, in-house testing services, product manufacturing and packaging, and quality control. BioSkryb plans to double its current workforce by the end of next year to a total of 50 highly skilled professionals, including genetic researchers, chemists, software engineers and developers, program managers, and quality control personnel.
“This new facility not only provides us an opportunity to grow our team but also deliver higher innovation to our customers, as we give them an unparalleled view of the specific genetic changes at the cellular level that are driving disease,” said Jay West, Ph.D., CEO and cofounder of BioSkryb Genomics. “Whether customers use our ResolveDNA products in their own lab or have our team analyze samples at our facility, we provide an unprecedented resolution of genomic heterogeneity so researchers and clinicians can understand genetic diversity at the single-cell level and make transformative discoveries to improve human health.”
BioSkryb’s Primary Template-directed Amplification (PTA) technology is a novel whole genome amplification approach that amplifies the genomes of single cells in a more accurate, uniform, and reproducible manner than previous methods. The Company’s ResolveDNA product line accurately and uniformly reproduce genomes of single cells to provide high-quality, scalable analysis of single-cell genomic heterogeneity. The company also has an end-to-end workflow solution, including BaseJumper, a cloud-based bioinformatics platform that allows users to explore single-cell human genomic datasets generated with ResolveDNA products.
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. The Company’s proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb’s solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today. For more information, please visit: www.bioskryb.com.
Company Contact: Rob Kaizerman, firstname.lastname@example.org, +1.919.370.0841